Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension

What Was Tested

This randomized controlled trial paper looks at Angiotensin II in the context of low blood pressure and orthostatic hypotension.

Angiotensin II receptor antagonists have become clinically available for the treatment of arterial hypertension.

Presently, there is little information about their effects on BP, proteinuria, and renal function in patients with moderate or advanced renal failure.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

Changes in glomerular permselectivity were assessed by measuring the fractional clearances of neutral dextrans by HPLC gel-permeation chromatography.

What Was Measured

Topics PubMed links to this paper include Albuminuria, Angiotensin II, Antihypertensive Agents, Blood Pressure, Blood Urea Nitrogen, Creatinine and Dextrans.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with low blood pressure and orthostatic hypotension.

The publication is from 1998 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.